Basic | |
---|---|
Market Cap | $6.02B |
Price | $22.05 |
52 Week Range | 10.95-24.6 |
Beta | 0.59 |
Margins | |
Gross Profit Margin | 63.94% |
Operating Profit Margin | 20.06% |
Net Profit Margin | 14.58% |
Valuation (TTM) | |
P/E Ratio | 42.81 |
Price to Sales Ratio | 6.41 |
Price to Book Ratio | 6.61 |
PEG Ratio | 2.89 |
Biotechnology
Healthcare
2,806
2009-11-16T00:00:00.000Z
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
45 45 74 75 76
Boge Alle 6-8, Horsholm, 2970, DK